References
- Drummond M. 1991. Economic evaluation of pharmaceuticals: science or marketing? Working Papers 091chedp, Centre for Health Economics, University of York.
- Peter JN, Thorat T, Shi J, et al. The changing face of the cost-utility literature, 1990–2012. Value in Health. 2015;18:271–277.
- Claxton K, Martin S, Soares M, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol. Assess. 2015;19(14):1–503.
- Greenberg D, Neumann PJ. Cost-effectiveness analysis expands its reach worldwide. Value Health Reg Issues. 2016;10:101–102.
- Cookson R, Mirelman AJ, Griffin S, et al. Using cost-effectiveness analysis to address health equity concerns. Value Health. 2017;20(2):206–212.
- Pandya BJ, Yang H, Schmeichel C, et al. A budget impact analysis of gilteritinib for the treatment of relapsed or refractory FLT3mut + acute myeloid leukemia in a US health plan. J Med Econ. 2021;24(1):19–28.
- Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–1740.
- Petrou P. Elucidating value: the role of cost-effectiveness analysis in the decision-making process for the management of BRAF V600E/K mutation-positive melanoma. J Med Econ. 2019;22(12):1241–1242.
- Petrou P. Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy. Expert Rev Pharmacoecon Outcomes Res. 2019;19(5):529–536.
- McKie J, Richardson J. The rule of rescue. Soc Sci Med. 2003;56(12):2407–2419.
- Alkhatib NS, Abraham I. The six Delta platform for outcome-based contracting for pharmaceuticals. J Med Econ. 2020;23(11):1209–1214.
- Kolasa K, Zwolinski KM, Kalo Z, et al. Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs. Orphanet J Rare Dis. 2016;11:23.